UB Paderborn / Katalog / Suche / in CDI

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

The Lancet (British edition), 2017-01, Vol.389 (10066), p.255-265

2017

Volltextzugriff (PDF)

Editorial: Small cell lung cancer: New drugs and strategies

Frontiers in medicine, 2023-01, Vol.10, p.1140642-1140642

2023

Volltextzugriff (PDF)

Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.140-150

2021

Volltextzugriff (PDF)

ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)

Clinical lung cancer, 2020-01, Vol.21 (1), p.15-20

2020

Volltextzugriff (PDF)

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

European journal of cancer (1990), 2021-05, Vol.148, p.24-35

2021

Volltextzugriff (PDF)

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001403

2020

Volltextzugriff (PDF)

Budget Impact di afatinib per il trattamento in prima linea del Non Small Cell Lung Cancer (NSCLC) con mutazioni non comuni EGFR

Global & regional health technology assessment (Online), 2022-01, Vol.9, p.22-29

2022

Volltextzugriff (PDF)

Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations

Global & regional health technology assessment (Online), 2022-01, Vol.9 (1), p.22-29

2022

Volltextzugriff (PDF)

Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy

Thoracic cancer, 2022-02, Vol.13 (3), p.483-488

2022

Volltextzugriff (PDF)

Focus on Nivolumab in NSCLC

Frontiers in medicine, 2016-12, Vol.3, p.67-67

2016

Volltextzugriff (PDF)

Isotretinoin Plus Clindamycin Seem Highly Effective Against Severe Erlotinib-Induced Skin Rash in Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2010-10, Vol.5 (10), p.1662-1663

2010

Volltextzugriff (PDF)

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Journal for immunotherapy of cancer, 2021-04, Vol.9 (4), p.e002421

2021

Volltextzugriff (PDF)

Budget Impact di afatinib per il trattamento in prima linea del Non Small Cell Lung Cancer (NSCLC) con mutazioni non comuni EGFR

Global & regional health technology assessment (Online), 2022-01, Vol.9, p.22-29

2022

Volltextzugriff (PDF)

Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

European journal of cancer (1990), 2021-06, Vol.150, p.224-231

2021

Volltextzugriff (PDF)

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

Thoracic cancer, 2021-03, Vol.12 (6), p.880-889

2021

Volltextzugriff (PDF)

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

The Lancet (British edition), 2012-12, Vol.380 (9859), p.2095-2128

2012

Volltextzugriff (PDF)

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Lancet, 2018-11, Vol.392 (10159), p.1859-1922

2018

Volltextzugriff (PDF)

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

The Lancet (British edition), 2017-09, Vol.390 (10100), p.1260-1344

2017

Volltextzugriff (PDF)

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

The Lancet (British edition), 2012-12, Vol.380 (9859), p.2163-2196

2012

Volltextzugriff (PDF)

Global Cardiovascular and Renal Outcomes of Reduced GFR

Journal of the American Society of Nephrology, 2017-07, Vol.28 (7), p.2167-2179

2017

Volltextzugriff (PDF)

Economic assessment of NGS testing workflow for NSCLC in a healthcare setting

Heliyon, 2024-04, Vol.10 (7), p.e29272-e29272, Article e29272

2024

Volltextzugriff (PDF)

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Clinical lung cancer, 2020-11, Vol.21 (6), p.498-508.e2

2020

Volltextzugriff (PDF)

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma

Cancer, 2004-01, Vol.100 (2), p.279-287

2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Editorial: Small cell lung cancer: New drugs and strategies

Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Budget Impact di afatinib per il trattamento in prima linea del Non Small Cell Lung Cancer (NSCLC) con mutazioni non comuni EGFR

Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations

Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy

Focus on Nivolumab in NSCLC

Isotretinoin Plus Clindamycin Seem Highly Effective Against Severe Erlotinib-Induced Skin Rash in Advanced Non-small Cell Lung Cancer

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Budget Impact di afatinib per il trattamento in prima linea del Non Small Cell Lung Cancer (NSCLC) con mutazioni non comuni EGFR

Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

Global Cardiovascular and Renal Outcomes of Reduced GFR

Economic assessment of NGS testing workflow for NSCLC in a healthcare setting

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma

Suchergebnisse filtern